CD274 and esophageal squamous cell carcinoma: In patients with ESCC PD-L1 CPS ≥ 10, ORR was 59.1% (26/44; 3 CRs; 23 PRs) in the pembrolizumab–chemotherapy group and 31.3% (10/32; 1 CR; 9 PRs) in the placebo–chemotherapy group; median DOR (range) was 10.5 months (2.3 + to 41.3 +) and 4.4 months (3.5 to 17.0), respectively.